Denca is under control at SAFC plant in Scotland
Will supply full control system for IPB2 facility at Irvine
The project involves building and automating a cell culture media, reagents and buffer solutions manufacturing system, CIP system, WFI/SIP system and filling system at the SAFC facility.
Denca, based in Widnes, Cheshire, will supply a full control system consisting of E&I design, manufacture of system control panels, including motor control panel, PLC/instrument control panel and multiple remote I/O, solenoid, HMI panels, system software and associated validation documentation to GAMP (Good Automated Manufacturing Practices), installation and testing/commissioning through to client handover.
You may also like
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows